Concurrent nimotuzumab and intensity‐modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma

Abstract

AbstractBecause of the common physical condition, reduced organ function, and comorbidities, elderly patients with nasopharyngeal carcinoma (NPC) are often underrepresented in clinical trials. The optimal treatment of elderly patients with locally advanced NPC remains unclear. The purpose of this study was to evaluate the efficacy of concurrent nimotuzumab combined with intensity‐modulated radiotherapy (IMRT) in elderly patients with locally advanced NPC. We conducted a single‐arm, phase II trial for elderly patients with stage III–IVA NPC (according to UICC–American Joint Committee on Cancer TNM classification, 8th edition). All patients received concurrent nimotuzumab (200 mg/week, 1 week prior to IMRT) combined with IMRT. The primary end‐point was complete response (CR) rate. The secondary end‐points were survival, safety, and geriatric assessment. Between March 13, 2017 and November 12, 2018, 30 patients were enrolled. In total, 20 (66.7%) patients achieved CR, and objective response was observed in 30 (100.0%) patients 1 month after radiotherapy. The median follow‐up time was 56.05 months (25th–75th percentile, 53.45–64.56 months). The 5‐year locoregional relapse‐free survival, distant metastasis‐free survival, cancer‐specific survival, disease‐free survival, and overall survival were 89.4%, 86.4%, 85.9%, 76.5%, and 78.8%, respectively. Grade 3 mucositis occurred in 10 (33%) patients and grade 3 pneumonia in 3 (10%) patients. Concurrent nimotuzumab combined with IMRT is effective and well‐tolerated for elderly patients with locally advanced NPC.